Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 9/20 | 0.35 |
| ▸ | CA1 | P00915 | 9/20 | 0.35 |
| ▸ | CA2 | P00918 | 9/20 | 0.35 |
| ▸ | CA9 | Q16790 | 9/20 | 0.35 |
| ▸ | CA7 | P43166 | 7/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256 | 1.00 | TSHR (0.50) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL19257 | 1.00 | TSHR (0.50) | TSHRHCAR2CA12CA1CA2 | |
| Water SCHEMBL30250355 | 0.97 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL22690761 | 0.97 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL28883041 | 0.97 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL29860029 | 0.97 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL31071641 | 0.97 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| Bicarbonate SCHEMBL2348361 | 0.92 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL23884961 | 0.89 | TSHR (0.42) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL15843149 | 0.89 | TSHR (0.42) | TSHRHCAR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-113365632-B | Aminopyrimidine compounds | 卡都瑞恩医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023218149-A1 | MIRROR THAT IS EASILY REMOVABLE FROM A SUPPORT TO WHICH IT HAS BEEN GLUED | SAINT-GOBAIN GLASS FRANCE (FR) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023186893-A1 | ADHESIVE COMPOSITION FOR A GLASS ITEM COMPRISING EXPANSION MEANS AND LAMINATED GLAZING UNIT FOR A MOTOR VEHICLE COMPRISING SUCH A COMPOSITION | SAINT-GOBAIN GLASS FRANCE (FR) | 2023-10-05 | — | — | WO | disclosed |
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3856188-B1 | AMINOPYRIMIDINE COMPOUND | CARDURION PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4161522-A1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | Merck Sharp & Dohme LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-113979981-B | Sulfhydryl response type dealkalized site capture reagent and application | 天津医科大学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2008037784-A1 | QUINOLINONE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-03 | — | — | WO | disclosed |
| US-20070088170-A1 | Novel compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2007-04-19 | — | — | US | disclosed |
| US-20070088170-A1 | Novel compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2007-04-19 | — | — | US | disclosed |
| CN-1935860-A | Method for producing ethylene-vinyl acetate copolymer chlorinated resin by acid phase process | UNIV HEFEI POLYTECHNIC (CN) | 2007-03-28 | — | — | CN | disclosed |
| CN-1821323-A | Water dispersion chromium-free single component silicon steel insulation paint and its preparing method | AOER CHEMICAL CO LTD WUXI CITY (CN) | 2006-08-23 | — | — | CN | disclosed |
| CN-1137247-C | Polymer-type efficient demulsifier for emulsion of crude oil and its synthesizing process | 东南大学 | 2004-02-04 | — | — | CN | disclosed |
| CN-1118495-C | Water-dispersible polymer and coating composition containing the same | DEXTER CORP (US) | 2003-08-20 | — | — | CN | disclosed |
| CN-1317544-A | Polymer-type efficient demulsifier for emulsion of crude oil and its synthesizing process | UNIV DONGNAN (CN) | 2001-10-17 | — | — | CN | disclosed |
| CN-1211261-A | Water-dispersible polymer and coating composition containing the same | DEXTER CORP (US) | 1999-03-17 | — | — | CN | disclosed |
| CN-1039379-A | PRESSURE-SENSITIVE ADHESIVE SHEETS | KANSAI PAINT CO LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088170-A1 | Novel compounds | FFAR2, GPR119, ALOX12 | TSHR 2384/4885HCAR2 40/4885CA12 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.